CD1d-restricted T (natural killer T [NKT]) cells are important for controlling a herpes simplex virus (HSV) infection. One of the mechanisms of immune evasion by HSV is to downregulate CD1d-mediated activation of NKT cells. VP22 is an HSV-1-encoded protein responsible for reorganizing the host cell's cytoskeletal network and viral spreading. We have previously shown that modification of the cytoskeleton can alter CD1d-mediated antigen presentation. In this study, we found that an HSV-1 lacking VP22 (ΔUL49) was impaired in its ability to inhibit CD1d-mediated antigen presentation compared with the wild-type (WT) virus; this was reversed by a repair virus (UL49R) in CD1d-expressing cells. We further demonstrated that CD1d recycling was inhibited by infection with WT and UL49R, but not the ΔUL49 virus. Ectopic expression of VP22 in CD1d-expressing cells complemented the VP22-deficient virus in inhibiting antigen presentation. Moreover, inhibiting viral protein synthesis rescued VP22-dependent inhibition of CD1d antigen presentation. In conclusion, our findings suggest that VP22 is required (but not sufficient) for the inhibition of CD1d-mediated antigen presentation by an HSV-1 infection.
Get full access to this article
View all access options for this article.
References
1.
AhnK, MeyerTH, UebelS, et al.Molecular mechanism and species specificity of TAP inhibition by herpes simplex virus ICP47. Embo J, 1996; 15:3247–3255.
2.
AsaiR, OhnoT, KatoA, et al.Identification of proteins directly phosphorylated by UL13 protein kinase from herpes simplex virus 1. Microbes Infect, 2007; 9:1434–1438.
3.
AshkarAA, and RosenthalKL. Interleukin-15 and natural killer and NKT cells play a critical role in innate protection against genital herpes simplex virus type 2 infection. J Virol, 2003; 77:10168–10171.
4.
BaileyJC, IyerAK, RenukaradhyaGJ, et al.Inhibition of CD1d-mediated antigen presentation by the TGF-beta/Smad signaling pathway. Immunology, 2014; 143:679–691.
5.
BanovicT, YanillaM, SimmonsR, et al.Disseminated varicella infection caused by varicella vaccine strain in a child with low invariant natural killer T cells and diminished CD1d expression. J Infect Dis, 2011; 204:1893–1901.
6.
BosnjakL, SahlstromP, Paquin-ProulxD, et al.Contact-dependent interference with invariant NKT cell activation by herpes simplex virus-infected cells. J Immunol, 2012; 188:6216–6224.
7.
BriglM, and BrennerMB. CD1: antigen presentation and T cell function. Annu Rev Immunol, 2004; 22:817–890.
8.
CornishAL, KeatingR, KyparissoudisK, et al.NKT cells are not critical for HSV-1 disease resolution. Immunol Cell Biol, 2006; 84:13–19.
9.
DewberryEJ, DunkerleyE, and DuffyC. Purification of full-length VP22 from cells infected with HSV-1: a two-pronged approach for the solubilization and purification of viral proteins for use in biochemical studies. J virol Methods, 2012; 183:180–185.
10.
DuffyC, LavailJH, TauscherAN, et al.Characterization of a UL49-null mutant: VP22 of herpes simplex virus type 1 facilitates viral spread in cultured cells and the mouse cornea. J Virol, 2006; 80:8664–8675.
11.
DuffyC, MbongEF, and BainesJD. VP22 of herpes simplex virus 1 promotes protein synthesis at late times in infection and accumulation of a subset of viral mRNAs at early times in infection. J Virol, 2009; 83:1009–1017.
12.
ElliottG, and O'HareP. Intercellular trafficking and protein delivery by a herpesvirus structural protein. Cell, 1997; 88:223–233.
13.
ElliottG, and O'HareP. Herpes simplex virus type 1 tegument protein VP22 induces the stabilization and hyperacetylation of microtubules. J Virol, 1998; 72:6448–6455.
14.
ElliottG, O'ReillyD, and O'HareP. Phosphorylation of the herpes simplex virus type 1 tegument protein VP22. Virology, 1996; 226:140–145.
15.
ElliottGD, and MeredithDM. The herpes simplex virus type 1 tegument protein VP22 is encoded by gene UL49. J Gen Virol, 1992; 73 (Pt 3):723–726.
16.
FruhK, AhnK, DjaballahH, et al.A viral inhibitor of peptide transporters for antigen presentation. Nature, 1995; 375:415–418.
17.
GalloRM, KhanMA, ShiJ, et al.Regulation of the actin cytoskeleton by rho kinase controls antigen presentation by CD1d. J Immunol, 2012; 189:1689–1698.
18.
GodfreyDI, MacDonaldHR, KronenbergM, et al.NKT cells: what's in a name?. Nat Rev Immunol, 2004; 4:231–237.
19.
Grubor-BaukB, SimmonsA, MayrhoferG, et al.Impaired clearance of herpes simplex virus type 1 from mice lacking CD1d or NKT cells expressing the semivariant Vα14-Jα281 TCR. J Immunol, 2003; 170:1430–1434.
20.
HillA, JugovicP, YorkI, et al.Herpes simplex virus turns off the TAP to evade host immunity. Nature, 1995; 375:411–415.
21.
KoelleDM, and CoreyL. Herpes simplex: insights on pathogenesis and possible vaccines. Annu Rev Med, 2008; 59:381–395.
22.
LeibDA. Counteraction of interferon-induced antiviral responses by herpes simplex viruses. Curr Top Microbiol Immunol, 2002; 269:171–185.
23.
LevyO, OrangeJS, HibberdP, et al.Disseminated varicella infection due to the vaccine strain of varicella-zoster virus, in a patient with a novel deficiency in natural killer T cells. J Infect Dis, 2003; 188:948–953.
24.
LinR, NoyceRS, CollinsSE, et al.The herpes simplex virus ICP0 RING finger domain inhibits IRF3- and IRF7-mediated activation of interferon-stimulated genes. J Virol, 2004; 78:1675–1684.
25.
LiuJ, GlossonNL, DuW, et al.A Thr/Ser dual residue motif in the cytoplasmic tail of human CD1d is important for the down-regulation of antigen presentation following a herpes simplex virus 1 infection. Immunology, 2013; 140:191–201.
26.
LiuJ, ShajiD, ChoS, et al.A threonine-based targeting signal in the human CD1d cytoplasmic tail controls its functional expression. J Immunol, 2010; 184:4973–4981.
27.
MaY, and HeB. Recognition of herpes simplex viruses: toll-like receptors and beyond. J Mol Biol, 2014; 426:1133–1147.
28.
MbongEF, WoodleyL, DunkerleyE, et al.Deletion of the herpes simplex virus 1 UL49 gene results in mRNA and protein translation defects that are complemented by secondary mutations in UL41. J Virol, 2012; 86:12351–12361.
29.
MouzakitisG, McLauchlanJ, BarrecaC, et al.Characterization of VP22 in herpes simplex virus-infected cells. J Virol, 2005; 79:12185–12198.
30.
NeumannJ, Eis-HubingerAM, and KochN. Herpes simplex virus type 1 targets the MHC class II processing pathway for immune evasion. J Immunol, 2003; 171:3075–3083.
31.
NoporaK, BernhardCA, RiedC, et al.MHC class I cross-presentation by dendritic cells counteracts viral immune evasion. Front Immunol, 2012; 3:348.
32.
PotelC, and ElliottG. Phosphorylation of the herpes simplex virus tegument protein VP22 has no effect on incorporation of VP22 into the virus but is involved in optimal expression and virion packaging of ICP0. J Virol, 2005; 79:14057–14068.
33.
RafteryMJ, WinauF, KaufmannSH, et al.CD1 antigen presentation by human dendritic cells as a target for herpes simplex virus immune evasion. J Immunol, 2006; 177:6207–6214.
34.
RafteryMJ, WolterE, FillatreauS, et al.NKT cells determine titer and subtype profile of virus-specific IgG antibodies during herpes simplex virus infection. J Immunol, 2014; 192:4294–4302.
35.
RaoP, PhamHT, KulkarniA, et al.Herpes simplex virus 1 glycoprotein B and US3 collaborate to inhibit CD1d antigen presentation and NKT cell function. J Virol, 2011; 85:8093–8104.
36.
RobertsTJ, SriramV, SpencePM, et al.Recycling CD1d1 molecules present endogenous antigens processed in an endocytic compartment to NKT cells. J Immunol, 2002; 168:5409–5414.
37.
SciortinoMT, TaddeoB, Giuffre-CucullettoM, et al.Replication-competent herpes simplex virus 1 isolates selected from cells transfected with a bacterial artificial chromosome DNA lacking only the UL49 gene vary with respect to the defect in the UL41 gene encoding host shutoff RNase. J Virol, 2007; 81:10924–10932.
38.
TaddeoB, SciortinoMT, ZhangW, et al.Interaction of herpes simplex virus RNase with VP16 and VP22 is required for the accumulation of the protein but not for accumulation of mRNA. Proc Natl Acad Sci U S A, 2007; 104:12163–12168.
39.
TanakaM, KatoA, SatohY, et al.Herpes simplex virus 1 VP22 regulates translocation of multiple viral and cellular proteins and promotes neurovirulence. J Virol, 2012; 86:5264–5277.
40.
TemmeS, Eis-HubingerAM, McLellanAD, et al.The herpes simplex virus-1 encoded glycoprotein B diverts HLA-DR into the exosome pathway. J Immunol, 2010; 184:236–243.
41.
TomazinR, HillAB, JugovicP, et al.Stable binding of the herpes simplex virus ICP47 protein to the peptide binding site of TAP. Embo J, 1996; 15:3256–3266.
42.
van LeeuwenH, ElliottG, and O'HareP. Evidence of a role for nonmuscle myosin II in herpes simplex virus type 1 egress. J Virol, 2002; 76:3471–3481.
43.
XiongR, RaoP, KimS, et al.Herpes simplex virus 1 US3 phosphorylates cellular KIF3A to downregulate CD1d expression. J Virol, 2015; 89:6646–6655.
44.
YorkIA, RoopC, AndrewsDW, et al.A cytosolic herpes simplex virus protein inhibits antigen presentation to CD8+ T lymphocytes. Cell, 1994; 77:525–535.
45.
YuanW, DasguptaA, and CresswellP. Herpes simplex virus evades natural killer T cell recognition by suppressing CD1d recycling. Nat Immunol, 2006; 7:835–842.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
